Found 128 matching trials
Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C PHASE3 This study is to evaluate the overall efficacy, and safety profile of the t...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C PHASE2 This phase 2b study will evaluate the efficacy and safety of 16 and 24 week...
Show More Learn More & Join Trial
Effect of Boceprevir on HCV-specific T Cell Responses N/A Analysis of HCV-specific T cell responses in patients treated with boceprev...
Show More Location
Unit of Infectious Diseases and Hepatology
Learn More & Join Trial
Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047) PHASE2 This is a multi-site, open-label trial evaluating the safety and efficacy o...
Show More Location
Multiple Locations
Learn More & Join Trial
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects PHASE1 The purpose of this study is to determine the Safety and Pharmacokinetics o...
Show More Location
Multiple Locations
Learn More & Join Trial
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment PHASE2 The purpose of this study is to determine whether BMS-790052 added to Pegin...
Show More Location
Alabama Liver & Digestive Specialists (Alds)
Learn More & Join Trial
GS-7977 With Ribavirin for Hepatitis C (SPARE) PHASE1 Background:
\- GS-7977 is a new drug that is being developed to treat hepa...
Show More Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
Learn More & Join Trial
GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus PHASE2 This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Eval...
Show More Location
Multiple Locations
Learn More & Join Trial
SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection PHASE3 This study will assess the efficacy, safety, and tolerability of 16 or 24 w...
Show More Location
Multiple Locations
Learn More & Join Trial
Combination Therapy for Chronic Hepatitis C Infection PHASE2 Background:
\- GS-7977, GS-5885, GS-9669, and GS-9451 are new drugs for tr...
Show More Location
Unity Health Care, Inc./DC General
Learn More & Join Trial